Clinical endocannabinoid deficiency: what the theory says and what is known

A theory, not a diagnosis

You may have seen the phrase "clinical endocannabinoid deficiency," or CECD, used to explain why cannabis seems to help some people with migraine, fibromyalgia, or irritable bowel syndrome (IBS). It is an interesting idea with a real scientific history. It is also a hypothesis, not an established medical diagnosis. Here is what the theory says, what evidence exists, and what is still missing.

First, the endocannabinoid system

The body makes its own cannabinoid-like chemicals, called endocannabinoids. The two best known are anandamide and 2-AG. Together with cannabinoid receptors and the enzymes that make and break down these chemicals, they form what researchers call the endocannabinoid system (ECS). THC and other compounds in cannabis act on parts of this same system, which is why scientists study it so closely.

What the CECD hypothesis proposes

Neurologist Ethan Russo first presented the idea in 2001 and explored it in more depth in a 2004 paper in Neuroendocrinology Letters. In a 2016 follow-up review, he summarized the core idea: everyone has an underlying "endocannabinoid tone," and in some people, whether from birth or acquired later, that tone may become deficient and contribute to illness.

Russo pointed to migraine, fibromyalgia, and IBS as the main candidates. These conditions often overlap in the same people, involve heightened sensitivity to pain, and lack objective signs on standard tests. His reasoning was that a shared underlying problem might help explain all three.

One piece of context: when the 2004 paper was written, Russo was a senior medical advisor at GW Pharmaceuticals, a company that develops cannabinoid medicines. That does not make the idea wrong, but it is worth knowing that much of the writing on CECD comes from its originator and from researchers who favor cannabinoid treatments.

What evidence exists

Russo's 2016 review lays out the strongest findings in support of the theory:

• Migraine. One study measured anandamide in the spinal fluid of 15 people with chronic migraine and 20 people without it, and found significantly lower levels in the migraine group. Russo called this perhaps the strongest evidence for the theory. Another small study (20 people per group) reported lower endocannabinoid levels in the blood platelets of people with migraine.
• PTSD. Small studies have reported lower endocannabinoid levels and differences in cannabinoid receptor imaging in people with post-traumatic stress disorder.
• Overlap between conditions. Migraine, fibromyalgia, and IBS frequently occur together, which fits the idea of a shared cause, though it does not prove one.

What is missing

These findings are intriguing, but they leave big gaps:

• Small studies. Much of the human evidence comes from studies of a few dozen people.
• Cause or effect? Finding lower endocannabinoid levels in people who already have a condition does not show that the low levels caused it. They could be a result of the condition, or of something else entirely.
• No accepted test or definition. CECD is not a recognized diagnosis, and doctors do not have a standard way to measure "endocannabinoid tone" in a patient. Russo himself noted that when the theory was first proposed, objective proof and formal clinical trial data were lacking.
• Limited treatment evidence. For IBS, the 2017 National Academies report found no or insufficient evidence that the cannabinoid dronabinol is effective for symptoms, and NIH's NCCIH says there has been so little research that it is unknown whether cannabis helps. For chronic pain in general, the National Academies did find substantial evidence of benefit, but NCCIH describes it as modest, and the International Association for the Study of Pain does not endorse the general use of cannabinoids for pain.
• Relief is not proof. Even when someone feels better after using cannabis, that does not show they had a deficiency to begin with.

Risks worth knowing

Whatever the cause of your symptoms, cannabis is not risk-free. The CDC estimates that about 3 in 10 people who use cannabis have cannabis use disorder, with higher risk for people who start young or use often. The National Institute on Drug Abuse notes that higher THC concentrations have been associated with a greater likelihood of developing cannabis use disorder, and that cannabis can interact with other drugs. The National Academies also found substantial evidence linking cannabis use to a higher risk of car crashes.

Talk to your doctor

Migraine, fibromyalgia, and IBS are real conditions with established ways to evaluate and manage them. If you have ongoing pain, headaches, or digestive symptoms, see a doctor rather than assuming an endocannabinoid deficiency is the cause. If you are considering cannabis, tell your doctor or pharmacist what you use and how often so they can check for interactions with your other medicines. Do not stop or change prescribed treatment without talking to your prescriber first. Dispensary staff can explain products and labels, but they cannot diagnose conditions or give medical advice.

The bottom line

Clinical endocannabinoid deficiency is a thought-provoking hypothesis backed by some small, early studies. It has not been confirmed, there is no accepted way to diagnose it, and evidence that cannabis helps the conditions it is linked to remains limited. Keep an eye on the research, and keep your doctor in the loop.

This article is general information, not medical advice.

Sources

1. Russo EB. Clinical Endocannabinoid Deficiency (CECD): Can this Concept Explain Therapeutic Benefits of Cannabis in Migraine, Fibromyalgia, Irritable Bowel Syndrome and other Treatment-Resistant Conditions? Neuroendocrinology Letters, 2004 (reprinted 2008).
2. Russo EB. Clinical Endocannabinoid Deficiency Reconsidered: Current Research Supports the Theory in Migraine, Fibromyalgia, Irritable Bowel, and Other Treatment-Resistant Syndromes. Cannabis and Cannabinoid Research, 2016.
3. The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research (Summary). National Academies of Sciences, Engineering, and Medicine, National Academies Press, 2017.
4. Cannabis (Marijuana) and Cannabinoids: What You Need To Know. National Center for Complementary and Integrative Health, National Institutes of Health, last updated 2019.
5. IASP Position Statement on the Use of Cannabinoids to Treat Pain. International Association for the Study of Pain, 2021.
6. Cannabis Use Disorder. Centers for Disease Control and Prevention.
7. Cannabis (Marijuana). National Institute on Drug Abuse, National Institutes of Health.